Leveraging Delivering Partnering Global Affordable Innovation Presence Chemistry Vivimed Labs Ltd Investor Presentation – March 2019
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward looking statements. Vivimed Labs Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. page 2
1 Business Snapshot 2 Sector overview 3 Our Business Table of Content Leveraging Global Presence (UQUIFA & SONEAS) Partnering Innovation Delivering Affordable Chemistry Specialty Chemicals Business 4 Financial Performance page 3
Vivimed at a Glance Capsules and Bulk tablets generics Syrups Niche 1 and liquids generics API DIVISION 2 FDF DIVISION 1 7 CDMO Nasal New DIVISION sprays generics Branded Generics Ethical Ointments products Bulk generics Niche generics New generics Ethical products # Filings Anti-ulcer Antihistamine, sedative, hypnotic Anti-depressant Antiparasitic agent (veterinary) Antibiotic Analgesic Anti-convulsant Anthelmintic Antifungal Anti-Hypertensive Anti-parkinsonian Antihistamine, Antipsychotic, Anxiolytic Antiviral Mydriatic Anti-ulcerative Skeletal muscle relaxants Vasodilator Bone resorption inhibitor Analgesic/Narcotic Calcium channel blocker page 4
Vivimed Labs in Numbers 1991 12 2000+ Year of Foundation # of Employees # No. of Facilities 6 APIs, FDFs, and Across 3 Continents ( Europe, Asia, Specialty Chemicals North America) covering 5 countries # R&D Facilities Product Portfolio Market Presence ` 11,857 Mn ` 2,216 Mn ` 761 Mn Revenues (FY18) EBITDA (FY18) PAT (FY18) page 5
Business Snapshot page 6
Key Developments - Milestones 2011 2013 2015 2017 2018 UQUIFA Actavis Pharma Divested Investment by Soneas Personal care Orbimed Acquistion • $ 55 Mn acquisition • Rs. 122 cr acquisition Division • Added depth to the • Provided access to • $ 50 Mn Investment • € 15 Mn acquisition API portfolio regulated market – • Transformed UQUIFA in Mascerene, • Divested part of • Enabled servicing FDF business overseas subsidiary into an end-to-end Specialty Chemicals • USFDA approved European & American • Fund Deployment - solution provider business for an EV of market effectively facility with a capacity • Offered access to Debt reduction & Rs. 380 cr to produce 1.2 bn Development of API new / untapped • Divestment follows Solid Oral Dosages business geographies Company’s strategy of p.a. • Investment focusing on core testament to Pharmaceuticals Company’s proven business track record JV with Strides • 50:50 JV with Strides to develop and commercialize various ANDAs in US • Vertical Integration of APIs & exploitation of mutual formulation capabilities • Looking to achieve 5 ANDAs per year from this JV in the complex generics space page 7
Our Distinguished Clientele page 8
Management Team DR. V MANOHAR RAO SANTOSH VARALWAR SANDEEP VARALWAR MARK I ROBBINS Chairman Managing Director & CEO Executive Director & SBU – Head FDF CEO - UQUIFA • • • • Conceptualized and started ‘VVS First generation entrepreneur Associated with Vivimed since its Mr. Robbins has been the CEO of Pharmaceuticals and Chemicals Private incorporation and leads Vivimed’s UQUIFA since 1990 • Business growth strategy and leadership; Limited (“VVS”)’, (which now stands Healthcare FDF division • Focus on key global Client relationships Has had experience managing other merged with Vivimed Labs Limited). • Over 19 years of experience in chemical and pharmaceutical companies • Previously associated with Shipping • Retired as Joint Director of The manufacturing and marketing in the for 20 years Corporation of India Veterinary Biological and Research Healthcare industry • Holds a BSc (Hons) in Genetics and an Institute (VBRI). MBA • Post- graduation in Veterinary Sciences from Edinburgh University, U.K. and has more than 30 years experience in The Municipal Corporation of Hyderabad and Department of Animal Husbandry, Government of Andhra Pradesh (India). SAURABH SG RAMAKRISHNA CHUNDURI JOZSEF REPASI SANKETH VARALWAR Executive Director - Member of Advisory Board Managing Director - Soneas SBU – Head (Specialty Chemicals) UQUIFA Director – Vivimed Labs Europe Ltd. • • • • 9+ years of past experience in Qualified Chartered Accountant and Cost More than 25 years of experience in Seasoned Professional ,Over 2 decades Investment Management Accountant pharmaceutical research and of experience in Sales and Marketing in development. US/Europe. • • B.E. degree in Mechanical Engineering, Finance professional with varied • • MBA in Finance & International experience in finance and management Associated with Soneas from 1996. B.E. degree in Computer Engineering. Business; pursued courses in ‘emerging over a few decades. • • Msc. In Pharmaceutical Development Assumed responsibility as SBU head in FY business leadership’ at the IIM, • Associated with several companies from Eỏtvỏ s Lorâ nd University. 15 and registered a phenomenal growth Bangalore, London Business School and including DEL, Matrix Labs, Maa TV etc for the Spechem business. • INSEAD, Paris Head of Research and Development at and served as a director in many Prochem Ltd, UNIDO Headquarters page 9 companies. Vienna.
Business Divisions… Generic API CDMO Pharma Contract Manufacturing FDF Generic Branded Business JV (US) page 10
Business Divisions Global supplier of niche molecules and formulations (Pharmaceuticals) Integrated player – presence across critical components in value chain Product wise Sales Mix (%) Specialty US FDA approved world class manufacturing facilities Chemicals , 12% Active Pharmaceutical Ingredient & CDMO UQUIFA s.a., Spanish subsidiary with 80 years of experience with USFDA approved API, 50% FY18 manufacturing units in Spain(2) and Mexico(1) manufactures API for Pharmaceuticals and animal health industry globally FDF, 38% Accounts for 50% of the overall revenue Finished Dosage Formulation Value added business delivering quality formulations and offering novel drug systems Geography Mix (%) Present in generic, branded and contract manufacturing segments Accounts for 38% of the overall revenue Domestic, 12% Specialty Chemicals (under divestment) FY18 Manufactures Hair Dyes, Photochromic Dyes, Anti-Microbials and Imaging Chemicals Vivimed is a world leader in the development of innovative photochromic dyes Export, Vivimed has patented processes for novel dyes targeting a range of applications 88% page 11
Sector Overview Pharmaceuticals page 12
Pharmaceutical Industry – Overview (Global) $ 1.4 Tn $ 3.9 bn 37% $1415 - $1445 bn Global spending Spending on branded Increase in Global medicine on medicines by medicine in patent expiry spending by 2022 2022 (expected) developed market between 2018- (Forecasted) (past 5 years) as per 2022 IQVIA Institute Source: Industry Reports Total Value Total Value Total Value $725 bn $1,135 bn $1415 – 45 bn Source: Industry Reports page 13
Pharmaceutical Industry – Developed Markets $ 915-945 bn Pharmaceutical spending in developed markets by 2022 United States US pharmaceutical market is estimated to grow by 4-7% CAGR from US$ 466.6 Billion in 2017 to US$ 585-615 Billion in 2022 7.3% 4%-7% Price increases and introduction of new specialty medicines CAGR CAGR 2013-17 2018-22 to drive the growth Europe CAGR for the next five years for EU5 markets is estimated at 1-4%, with overall spending in these markets likely to escalate from US$ 154.4 Billion in 2017 to US$ 170-200 Billion in 2022 4.4% 1-4% Ageing population of countries and increased incidence of CAGR CAGR 2013-17 2018-22 chronic ailments to drive the growth page 14 Source: Industry Reports
Pharmaceutical Industry – Pharmerging Markets $ 345-375 bn Pharmaceutical spending in Pharmerging markets by 2022 2013-17 2018-22 Region / country 2017 2022 CAGR CAGR China 122.6 9.4% 145-175 5-8% Tier 2 Markets 67.3 11.2% 89-93 7-10% Brazil 33.1 11.5% 38-42 5-8% India 19.3 11.0% 26-30 9-12% 9-7% 6-9% Russia 14.9 10.8% 20-24 7-10% CAGR CAGR 2013-17 2018-22 Tier 3 markets 79.7 8.9% 95-125 6-9% Total 269.6 9.7% 345-375 6-9% Source: Industry Reports Branded generic medicines comprise the largest proportion of medicine spending in these economies (US$ per person/year) China, the largest pharmerging market, will grow at a modest 5-8% in the next half decade, reaching US$ 145-175 Billion in 2022 India and Russia are expected to grow faster, in comparison, averaging at 10% in the same time span, while the other pharmerging markets will average 6-9% India’s spending on medicines will propel its entry into the top 10 countries page 15 in 2018, and to the ninth position overall between 2019 and 2022
API & CDMO Business (UQUIFA & SONEAS) page 16
Recommend
More recommend
